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While analyzing the DNA methylome of multiple myeloma (MM), a plasma cell neoplasm, by whole-genome bisulfite se-
quencing and high-density arrays, we observed a highly heterogeneous pattern globally characterized by regional DNA
hypermethylation embedded in extensive hypomethylation. In contrast to the widely reported DNA hypermethylation
of promoter-associated CpG islands (CGIs) in cancer, hypermethylated sites in MM, as opposed to normal plasma cells,
were located outside CpG islands and were unexpectedly associated with intronic enhancer regions defined in normal B cells
and plasma cells. Both RNA-seq and in vitro reporter assays indicated that enhancer hypermethylation is globally associated
with down-regulation of its host genes. ChIP-seq and DNase-seq further revealed that DNA hypermethylation in these re-
gions is related to enhancer decommissioning. Hypermethylated enhancer regions overlapped with binding sites of B cell-
specific transcription factors (TFs) and the degree of enhancer methylation inversely correlated with expression levels of
these TFs in MM. Furthermore, hypermethylated regions in MM were methylated in stem cells and gradually became de-
methylated during normal B-cell differentiation, suggesting that MM cells either reacquire epigenetic features of undiffer-
entiated cells or maintain an epigenetic signature of a putative myeloma stem cell progenitor. Overall, we have identified
DNA hypermethylation of developmentally regulated enhancers as a new type of epigenetic modification associated with
the pathogenesis of MM.
[Supplemental material is available for this article.]
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Multiple myeloma (MM) is an aggressive and incurable neoplasm
characterized by clonal proliferation of plasma cells in the bone
marrow and a marked clinico-biological heterogeneity (Morgan
et al. 2012; Bergsagel et al. 2013). MM frequently arises from a pre-
malignant state known as monoclonal gammopathy of undeter-
mined significance (MGUS), although the precise molecular
mechanisms involved in the progression from MGUS to MM are
only partially understood. Various distinct genetic abnormalities
have been observed in bothMMandMGUS, including genemuta-
tions, chromosomal rearrangements, or aneusomies (Bergsagel
and Kuehl 2005; Chng et al. 2006; Chapman et al. 2011).
Besides genetic abnormalities, recent studies have shown that
epigenetic changes such as DNA methylation play an important
role in MM. Various reports indicate that DNA methylation pat-
terns are capable of distinguishing normal plasma cells (NPCs)
from MGUS and MM cells. The major differences between these
entities can be explained by the occurrence of DNA hypomethyla-
tion in malignant plasma cells (Salhia et al. 2010; Walker et al.
2011; Heuck et al. 2013). In addition to this DNA hypomethyla-
tion, some studies have demonstrated aberrant DNA hypermethy-
lation of promoter regions of different tumor suppressor genes
in MM, although the classical CpG island methylator phenotype
(CIMP) extensively observed in a wide variety of tumors (Issa
2004) has been rarely reported in MM (Martin et al. 2008).
Hypermethylation of RASD1, for example, has been correlated
with resistance of MM to dexamethasone (Nojima et al. 2009).
Inappropriate DNA methylation of TNFRSF18 (also known as
GITR) (Liu et al. 2013), MIR34B/C (Wong et al. 2011), or the com-
bined inactivation of genesGPX3, RBP1, SPARC, and TGFBI (Kaiser
et al. 2013) have been associated with poor prognosis, survival,
and disease progression in patients with MM.
In spite of these significant findings, the high-throughput
DNA methylation reports published so far in MM were restricted
to the study of promoter regions (Nojima et al. 2009; Salhia et al.
2010; Walker et al. 2011; Heuck et al. 2013; Kaiser et al. 2013).
Hence, the purpose of our study was to adopt a more extensive
and unbiased analysis of the DNA methylome, including promot-
ers, gene bodies, and intergenic regions in normal plasma cells
(NPC) and plasma cells from MGUS and MM patient samples.
Using this approach, we have identified that DNA methylation
of B cell-specific enhancer regions is a new phenomenon associat-
ed with MM pathogenesis.
Results
The DNA methylome of MM is globally characterized
by a large degree of heterogeneity
To analyze the DNAmethylome and define general epigenetic sig-
natures associated with plasma cell disorders, we applied the
HumanMethylation450 BeadChip (Illumina) to purified plasma
cells obtained from bone marrow samples of MM (n = 104) and
MGUS (n = 16) patients as well as normal bone marrows (n = 3
pools from four donors each) and nontumoral tonsils (n = 8)
(Supplemental Table 1). Unsupervised principal component anal-
ysis of the normalized DNAmethylation data identified a clear dis-
tinction between NPC and MM samples, with a larger degree of
heterogeneity in themyeloma plasma cells (Fig. 1A,B; Supplemen-
tal Fig. 1). Next, we further characterized this heterogeneity ofMM
by comparing it with other lymphoidmalignancies.We calculated
the medianmethylation value per case and measured the variabil-
ity per entity. The coefficient of variation (CV) was significantly
higher (P < 0.001) in MM (CV = 30.7) than in acute lymphoblastic
leukemia (ALL; CV = 7.9), chronic lymphocytic leukemia (CLL;
CV = 5.3), and diffuse large B cell lymphoma (DLBCL; CV = 10.4)
(Fig. 1C). This analysis shows that the extreme heterogeneity of
DNA methylation levels seems to be an epigenetic feature that is
specific for MM. To further characterize this variable pattern, we
sequenced the whole DNAmethylome at a single base pair resolu-
tion (>51-fold coverage per sample) of NPCs from bone marrow
and two MMs in which the HumanMethylation450 BeadChip in-
dicated extreme hyper- or hypomethylation (white arrows in Fig.
1B; Supplemental Tables 1, 2; Supplemental Fig. 1). Indeed, these
analyses validated the array data at the whole-genome level, with
the genome of MM1 being hypermethylated and that of MM2 be-
ing hypomethylated as compared to NPCs (Fig. 1D–F). Hence,MM
can show different methylomes, with a wide range of methylation
levels that range from globally hypo- to hypermethylated.
Detection of aberrant DNA methylation in MM and MGUS
To obtain a reliable whole-genome measure of the magnitude of
epigenetic changes in MM, we compared the methylation levels
of each MM sample with extreme methylation patterns and
NPCs. Sample MM1 showed 1,504,700 differentially methylated
regions (DMRs) covering a total of 2,158,824 CpG dinucleotides,
whereas MM2 had 1,875,824 DMRs covering 4,308,958 CpGs. As
previously suggested in Figure 1D, themajority of DMRs identified
in MM2 were hypomethylated, whereas MM1 showed less hypo-
methylation and increased hypermethylation levels (Fig. 2A,B).
Next, we attempted to generate a consensus differential
methylation signature of MGUS and MM in comparison with
NPCs, using microarray data of a large series of samples (Fig. 2C–
E). From 78,998 differentially methylated CpGs identified be-
tween MM and NPC, the great majority were hypomethylated
(98.3%). In MGUS, we detected 9388 differentially methylated
CpGs, of which 6874 (73.2%) were hypomethylated and 2514
(26.8%) hypermethylated (Fig. 2C–E; Supplemental Fig. 2). A
direct comparison between MM and MGUS revealed that the pro-
gression fromMGUS to MM seems to be associated with increased
hypomethylation in the absence of additional hypermethylation
events (Supplemental Fig. 3).
Applying an unsupervised analysis in order to compare the
DNA methylation profiles of clinically relevant MM subtypes
based on the presence or absence of cytogenetic alterations, i.e.,
hyperdiploidy, chromosomal translocations affecting the immu-
noglobulin heavy chain (IGH) locus and TP53 deletions, we did
not find any apparent association (Fig. 1B; Supplemental Fig. 4).
These results were confirmed using a supervised approach, in
which we observed only a few differentially methylated CpGs
between cytogenetic subgroups (Supplemental Fig. 5). However,
these findings do not rule out the possibility that other genetic
aberrations, not analyzed in our study, may be related to DNA
methylation changes, as shownpreviously inMMaswell as in oth-
er tumors (Weisenberger et al. 2006; Walker et al. 2011).
Hypo- and hypermethylated CpGs in MM are located in specific
genomic regions and enriched in particular chromatin states
Hypomethylated sites in MM and MGUS mainly occurred in re-
gions lacking CpG islands (CGI) and were predominantly located
in gene bodies and intergenic regions. Although both whole-ge-
nome bisulfite sequencing (WGBS) and HumanMethylation450
BeadChip showed this effect, the enrichment, when compared
with the background distribution, was particularly evident in the
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consensus signature (MM versus NPCs) derived from Human-
Methylation450 BeadChip. Interestingly, hypermethylated sites
also occurred in regions lacking CGIs (Supplemental Fig. 6).
In order to investigate the functional significance of aberrant
DNA methylation in MM, we annotated hypo- and hypermethy-
lated CpGs according to functional chromatin states recently de-
scribed by ChIP-seq in immortalized mature B cells (IMBCs)
(Ernst et al. 2011), which have a DNA methylation profile similar
to normal memory B cells and plasma cells (Supplemental Fig. 7).
As previously observed in colon cancer (Berman et al. 2011), the
great majority (75%–80%) of hypomethylated CpGs in MM and
MGUS, or those losing methylation in the progression from
MGUS to MM, were located in heterochromatic and late-replicat-
ing regions such as lamina-associated domains (LADs) (Fig. 2F;
Supplemental Figs. 3, 8). We analyzed the potential effect of this
epigenetic change and we found neither a morphological alter-
ation of the chromatin bound to the nuclear lamina by electron
microscopy nor a detachment of hypomethylated regions from
thenuclear lamina by 3D-FISH.We then studied the transcriptome
of 11 MM cases and four NPCs by RNA-seq, and we observed that
genes located in hypomethylated heterochromatic regions global-
ly showed low expression levels both in NPCs and MMs regardless
of their methylation status (Supplemental Fig. 9). Furthermore, fo-
cusing only on promoter regions undergoing demethylation, only
1.9% of the CpGs showed a significant correlation (P < 0.01) with
gene expression. These data suggest that heterochromatin hypo-
methylation seems to have a low impact on gene expression.
Remarkably, a large proportion of hypermethylated CpGs in
MM (n = 794; 59.9%; P < 1 × 10−12) (Supplemental Table 3) and
MGUS (n = 1656; 65.9%; P < 1 × 10−12) were located within en-
hancer regions (Figs. 2F, 3A; Supplemental Fig. 10), and in partic-
ular, within intronic enhancers (Supplemental Fig. 11). To
evaluate whether differential methylation of enhancers in MM
may be functionally relevant, we analyzed the expression of their
associated genes by RNA-seq. Overall, we observed a shift toward
an inverse correlation between enhancermethylation and their as-
sociated gene expression as compared to nonenhancer intronic re-
gions of the same genes (Fig. 3B–F; Supplemental Table 4), which
mostly took place in the absence of DNA methylation changes
in the corresponding promoter regions (Supplemental Fig. 12).
In fact, of the 50 genes with the strongest inverse correlation be-
tween enhancer methylation and gene expression, only two
(4%) showed concurrent promoter hypermethylation. We further
analyzed the consequences of differential DNAmethylation at en-
hancer regions and observed that treating a MM cell line with
5-azacytidine led to increased expression of SLC15A4 and PVT1
(Supplemental Fig. 13). Due to the unspecificity of this pharmaco-
logical treatment, we also performed reporter assays using a CpG-
Free Luciferase Vector (Klug and Rehli 2006). We cloned three en-
hancer regions into this vector, which showed variable levels of
correlation between DNA methylation and expression levels
(Supplemental Table 5). Luciferase activity analyzed in transient
transfection assays comparing unmethylated and in vitro methyl-
ated vectors revealed that upon enhancer methylation, the lucifer-
ase activity was reduced, further supporting our findings in
primary tumors (Fig. 3D–F).
Hypermethylation of B cell-specific enhancers in MM is associated
with enhancer decommissioning
After showing that DNA methylation is related to enhancer activ-
ity, we attempted to analyze the biological function of the genes
Figure 2. Differential DNA methylation in MM and MGUS as compared to NPCs. (A,B) Differentially methylated CpGs using WGBS data in (A) MM1
versus NPC and (B) MM2 versus NPC. (C,D) Differentially methylated CpGs identified using the HumanMethylation450 BeadChip data in (C) MGUS versus
NPC samples and (D) MM versus NPC samples. (E) Heatmap of significantly hypomethylated (left) or hypermethylated CpGs (right) in MM samples versus
NPC samples. (F) Relative distribution of differentially hypo- or hypermethylated CpGs across different functional chromatin states of the genome using
WGBS data (left) or HumanMethylation450 BeadChip data (right) as compared to their respective backgrounds (first column). The numbers inside
each cell point to the percentage of CpGs belonging to a particular chromatin state. (WG) Whole-genome; (HyperM) hypermethylated CpGs;
(HypoM) hypomethylated CpGs.
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with hypermethylated enhancers (631 genes associated with the
794 CpGs). A Gene Ontology analysis pointed to significant
enrichment of various terms associated with B-cell differentiation
(Supplemental Table 6). Furthermore, using transcription factor
binding sites (TFBSs) identified by ChIP-seq in the ENCODE
Project (Gerstein et al. 2012), we observed that hypermethylated
enhancers overlapped with binding sites of transcription factors
(TFs) associated with B-cell differentiation such as BCL11A,
BATF, EBF1, and PAX5 (Supplemental Table 7). These data led us
to investigate whether the DNA methylation levels of these en-
hancer regions aremodulated during normal B-cell differentiation.
We analyzed the DNA methylation profiles of seven B-cell differ-
entiation stages, including hematopoietic multipotent progeni-
tors, several immature B cells, naive B cells, germinal center B
cells, and plasma cells. In addition, we included embryonic stem
cells (ESCs) and IMBCs (Ernst et al. 2011) in the analysis, as well
as other B-cell neoplasms such as CLL (n = 139) (Kulis et al.
2012), ALL (n = 46) (Busche et al. 2013), and DLBCL (n = 40).
Surprisingly, the 794 enhancer-associated CpGs hypermethylated
inMMwere alsomethylated in ESCs and gradually lost DNAmeth-
ylation, finally becoming completely unmethylated in germinal
center B cells and terminally differentiated plasma cells (Fig. 4A).
We found that ALLs appear to maintain a methylation pattern re-
sembling their cellular origin (precursor B cell), whereas DLBCLs,
similarly to MM, show hypermethylation of B cell-specific en-
hancers when compared to their cell of origin (i.e., germinal center
B cells) (Supplemental Fig. 14).
Next, we studied whether enhancer hypermethylation in
MMwas accompanied by a change in the chromatin state.We per-
formed ChIP-seq with antibodies against monomethylated lysine
4 (H3K4me1) and acetylated lysine 27 (H3K27ac) of histone H3 in
NPCs and in the MM cell line U266, and also DNase-seq in the
latter. Data were compared to ESCs (showing hypermethylated en-
hancers, similar to MM) and IMBCs (with unmethylated enhanc-
ers, similar to NPCs). As shown in Figure 4B, the genomic areas
surrounding unmethylated enhancers in IMBCs show a clear en-
richment of H3K4me1 and H3K27ac as well as DNase hypersensi-
tive sites. In NPCs, the regions under study lost H3K27ac, but
H3K4me1 showed a strong signal, indicating that they maintain
their enhancer status. In contrast, methylated enhancers in ESCs
and theU266 cell line actually represent decommissioned enhanc-
ers (Whyte et al. 2012; Rivera and Ren 2013) lacking all the
Figure 3. Functional and transcriptional analysis of hypermethylated enhancer regions in MM. (A) Percentage of hypermethylated CpGs associated with
enhancer regions in MGUS and MM patient samples using HumanMethylation450 BeadChip data. (B) Density plot of correlation coefficients between
methylation levels of hypermethylated enhancers and the expression of their associated genes (cyan) using RNA-seq data. As control, intronic CpGs of
the same genes were studied excluding the enhancer associated ones (black dotted line). For this analysis, we used 663 CpGs (out of 794) annotated
to 574 genes with available gene expression, and 8956 CpGs in nonenhancer intronic regions of the same genes. (C ) A snapshot of the UCSC
Genome Browser showing the promoter (left) and the 3′ intronic enhancer region (right) of the SLC15A4 gene. Displayed tracks include the chromatin state
characterization in IMBCs and ChIP-seq data for H3K27ac, H3K4me1, and H3K4me3. DNAmethylation levels of NPCs andMM patient samples measured
by WGBS and HumanMethylation450 BeadChip are also shown. (D–F) Correlation analysis between DNA methylation levels of the hypermethylated en-
hancers and expression of the associated gene (left). In addition, we display the luciferase reporter activity data of the analyzed enhancer region (right)
located in the intron of (D) SLC15A4, (E) PVT1, and (F ) NCOR2. (MP) Minimal promoter; (MET) methylated; (UNMET) unmethylated.
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enhancer-associated features (Fig. 4B,C). Interestingly, 125 of the
794 enhancers with significant hypermethylation in MM cases
were unmethylated in the U266 MM cell line. Similarly to
IMBCs, these unmethylated B-cell enhancers were accompanied
by a chromatin structure linked to active enhancers in the MM
cell line (Fig. 4C). This finding is further supported by the fact
that enhancers (defined as such in IMBCs) hypomethylated in
IMBCs, NPCs, and the MM cell line, but hypermethylated in
ESCs, only showed active enhancer-related chromatin marks in
the first three (Supplemental Fig. 15).
Down-regulation of B cell-specific transcription factors
in MM is associated with enhancer hypermethylation
All the preceding results suggest that MMs acquire hypermethyla-
tion in enhancer regions that paradoxically undergo demethyla-
tion during normal B-cell differentiation (Fig. 4A). Since the
process of B-cell differentiation is guided by expression of stage-
specific TFs (Matthias and Rolink 2005; Kurosaki et al. 2010), the
binding of TFs to their target enhancers may result in demethyla-
tion. Several lines of evidence support this model in which DNA
demethylation during cell development is mediated by the pres-
ence of TFs, whose binding may block DNA methylation mainte-
nance after cell division (Stadler et al. 2011; Lee et al. 2012;
Feldmann et al. 2013; Hon et al. 2013; Kulis et al. 2013).
Interestingly, here we have observed the reverse process in plasma
cell disorders in which B cell-specific TF binding sites seem to
reacquire a chromatin state that is typical of undifferentiated
cells. Therefore, we postulate that down-regulation of B cell-specif-
ic TFs in MM cells could result in enhancer methylation and
decommissioning. To test this hypothesis, we analyzed the ex-
pression levels of B cell-specific TFs in MMs and NPCs by RNA-
seq and correlated them with the mean DNA methylation level
of the enhancers with altered methylation in MM. Interestingly,
for most of the B cell-specific TFs, we observed an inverse correla-
tion between their expression and methylation levels of their tar-
get enhancers (Fig. 5A). Among these, the expression of STAT5,
PAX5, NFATC1, and BATF showed a significant negative cor-
relation with DNA methylation levels of enhancers in normal
and neoplastic plasma cells (Pearson coefficient ranging from
−0.79 to −0.62, P < 0.05) (Fig. 5A–D; Supplemental Table 8).
Furthermore, variable expression of several of these TFs was coor-
dinated in MM patients (Fig. 5E), suggesting that the expression
level of a TF network, and not that of individual TFs, was associated
with the methylation levels of enhancers. In line with this find-
ing, the expression levels of genes regulated by enhancer methyl-
ation also showed a correlated expression among MM patients
(Supplemental Fig. 16).
Figure 4. DNAmethylation and chromatin features of hypermethylated enhancers in MM in the context of normal B-cell differentiation. (A) DNAmeth-
ylation levels of 794 enhancer-associated CpGs in seven B-cell differentiation stages, MGUS and MM patient samples, as well as ESCs (H1), IMBCs
(GM12878), and U266-MM cell lines. (B) ChIP-seq levels of H3K4me1 and H3K27ac, and DNase-seq data of 794 enhancer-associated CpGs in ESCs,
IMBCs, NPCs, and the U266 MM cell line. (C ) Density plot of H3K4me1, H3K27ac, and DNase levels in ESCs, IMBCs, NPCs, and the U266 MM cell
line. Among the 794 enhancer-associated CpGs in MM, those hypermethylated in U266 are shown in the top panel, whereas those unmethylated in
this cell line appear at the bottom. (MPP-CLP) Hematopoietic multipotent progenitors–common lymphoid progenitors; (ESCs) embryonic stem cells;
(IMBCs) immortalized mature B cells; (NPCs) normal plasma cells; (U266-MM) multiple myeloma derived cell line U266.
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Discussion
In this study, we have characterized the DNA methylome of nor-
mal and neoplastic plasma cells using a double approach. On the
one hand, we generated an epigenetic signature of common
DNA methylation changes in MGUS and MM by comparing
them to NPCs, using the HumanMethylation450 BeadChip in a
large series of patients. On the other hand, we analyzed the whole
DNA methylome at single base-pair resolution of two samples
from the extremes of the DNA methylation spectrum of MM.
This second approach allowed us to characterize the epigenetic
heterogeneity in MM, to define the boundaries of DMRs, and to
Figure 5. B cell-specific TFs’ expression correlates with DNA methylation levels of their binding sites in MM. (A) The upper part shows that hypermethy-
lated enhancers are enriched for binding sites of B cell-specific TFs. The lower part displays the correlation coefficients between TF expression andmeanDNA
methylation level of their respective binding sites with hypermethylation in MM. (∗) P < 0.05. (B–D) Scatter plots showing the association between TF ex-
pression and mean methylation level of their respective binding sites. Normal plasma cells are shown in blue and multiple myeloma samples are depicted
in red. (E) Correlation matrix of expression levels of TFs among the 11 MM cases with available RNA-seq data. Only those TFs from Awith at least 1.5-fold
enrichment (in log2) were used for this analysis.
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measure themagnitude ofDNAmethylation changes inMMat the
whole-genome level.
As shown in other studies (Salhia et al. 2010; Walker et al.
2011; Heuck et al. 2013), we describe a clear distinction in DNA
methylation patterns betweenmalignant andnormal plasma cells,
mostly in the form of hypomethylation in the former. Interesting-
ly, one of themajor features ofMM is the extreme heterogeneity of
median DNA methylation levels, which ranges from globally
hypo- to globally hypermethylated as compared toNPCs. This het-
erogeneity inMM is remarkably higher than in othermalignancies
of the B-cell lineage (Fig. 1C). Premalignant MGUS samples were
less heterogeneous than MM but shared a similar hypermethyla-
tion signature. In contrast, hypomethylation in MM was much
more extensive and heterogeneous than in MGUS, suggesting
that it may be related to progression fromMGUS to MM, as previ-
ously reported (Salhia et al. 2010; Walker et al. 2011; Heuck et al.
2013). In contrast to other studies (Walker et al. 2011), we did
not observe the epigenetic variability in MM to be associated
with particular genetic changes. However, we cannot rule out
the possibility that some genetic features, not analyzed in our
study, could be correlated with the heterogeneous DNA methyl-
ome. Although the causes of epigenetic heterogeneity in MM re-
quire further investigation, we postulate that this phenomenon
could be the consequence of both the DNA methylation pattern
of the founder plasma cell clone within the heterogeneous plasma
cell pool and the proliferative history of the neoplastic cells in a
particular case.
One of themost unexpected findings of our study is thatDNA
hypermethylation in MGUS and MM occurred in regions outside
CGIs. This finding contrasts with the classical cancer-associated
CIMP (Issa 2004; Fang et al. 2014) and recent whole-methylome
reports, in which hypermethylation is invariably associated with
CGIs and CGI shores close to promoter regions (Berman et al.
2011; Hansen et al. 2011; Kulis et al. 2012). Remarkably, a large
proportion of hypermethylated CpGs in MM and MGUS were lo-
cated within intronic regions with enhancer-related chromatin
marks in nonmalignant mature B cells and plasma cells.
Analyzing the methylation of these regions in the context of B-
cell differentiation, we observed a gradual demethylation from
stem cells to plasma cells. Hence, the observed methylation pat-
tern of these regions inMM is similar to undifferentiated precursor
and stem cells. This finding may reveal new potential insights in
the biology of the disease. On the one hand, it may represent a
de novo epigenetic reprogramming in MM, leading to the acquisi-
tion of a methylation pattern related to stemness. On the other
hand, we cannot rule out that the observed pattern could reflect
an epigenetic imprint of initial premalignant phases of the disease
in progenitor cells.
Our analysis of the chromatin in B cells, plasma cells, andMM
revealed that enhancer hypermethylation in MM was associated
with enhancer decommissioning, as recently shown in prostate
and breast cancer (Taberlay et al. 2014). Several studies have pro-
vided evidence indicating that the binding of specific TFsmediates
the loss of DNAmethylation at regulatory elements during the cell
differentiation (Stadler et al. 2011; Lee et al. 2012; Feldmann et al.
2013; Hon et al. 2013; Kulis et al. 2013). Here, we have observed
that the hypermethylation and decommissioning of specific B-
cell enhancers in MM appear to be related to down-regulation of
a network of B-cell TFs. Similarly to the globally heterogeneous
methylation pattern, this hypermethylation of B-cell enhancers
also varied among different cases and may be useful to detect dis-
ease subtypes. Interestingly, ∼20% of the MM patients express the
B-cellmarker CD20 (SanMiguel et al. 1991).We speculate that this
MM subtypemay lack hypermethylation and decommissioning of
B-cell enhancers, allowing part of the B-cell signature to be main-
tained. In conclusion, our results suggest that MMs show a widely
heterogeneous DNA methylation pattern. Embedded into an ex-
tensive hypomethylated genome,we identifiedDNAhypermethy-
lation of developmentally regulated enhancers as a new epigenetic
feature of MM. The delineation of the precise role of enhancer
hypermethylation in MM pathogenesis and its potential useful-
ness in the clinical setting as a new source of epigenetic biomarkers
should be further investigated.
Methods
Patient samples and cell line
Purified plasma cells from bone marrow aspirations were obtained
from newly diagnosed patients of MM (n = 104) and MGUS (n =
16). As negative controls, we purified plasma cells fromhealthy do-
nors (eight tonsils and 12 bone marrows, the latter pooled into
three samples of four donors each). The MM cell line U266 was
kindly provided by Dr. Cigudosa (Spanish National Cancer
Centre-CNIO,Madrid, Spain). Further details on the biologicalma-
terials used in our study are described in the Supplemental
Material.
DNA methylation analysis
Whole-genome bisulfite sequencing and HumanMethylation450
BeadChip (Illumina) were carried out in order to analyze the
DNA methylation profile of MM, MGUS, normal plasma cells,
and the U266 MM cell line. Details on the experimental proce-
dures, annotation of CpG sites, detection of differentially methyl-
ated regions, and Gene Ontology analysis are described in the
Supplemental Material.
Analysis of RNA-seq data
RNA samples from 11 MMs (also analyzed by Human
Methylation450 BeadChip) and four NPCs from tonsils were se-
quenced using the standard Illumina protocol. Technical details
are described in the Supplemental Material.
Luciferase reporter assay
pCpGL empty vector and pCpGL-CMV/EF1 were kindly provided
byDr. Rehli (University Hospital, Regensburg, Germany). To prop-
erly initiate the transcription, a CpG free minimal promoter
(5′-AGAGGGTATATAATGGAAGCTTAACTTCCAG-3´) was also
cloned in the pCpGL empty vector (see details in the Supplemen-
tal Material).
ChIP-seq and DNase-seq
ChIP-seq was performed in NPCs and in the U266 cell line, and
DNase-seq was carried out only on the latter. Standard protocols
generated within the Blueprint Consortium were followed.
Protocol details can be found at http://www.blueprint-epigenome
.eu/index.cfm?p=7BF8A4B6-F4FE-861A-2AD57A08D63D0B58.
Mapped reads of the ChIP-seq data for H3K4me1 and
H3K27ac as well as DNase-seq data from the cell lines GM12878
and H1 were downloaded from the UCSC Genome Browser
(GRCh37/hg19 Assembly; http://genome-euro.ucsc.edu).
Read density around the 794 CpGs hypermethylated in MM
was calculated by seqMINER tool using a 5-kb window upstream
and downstream from the CpGs of interest (Ye et al. 2011).
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Analysis of transcription factor binding sites
We used ChIP-seq data from the ENCODE Project available at
the UCSC Genome Browser (http://genome.ucsc.edu/cgi-bin/
hgTrackUi?db=hg19&g=wgEncodeHaibTfbs) to obtain informa-
tion on transcription factor binding sites (TFBS) of a total of
163 TFs. The relative enrichment of each TFBS was calculated
for the 794 hypermethylated CpGs located in enhancer ele-
ments in comparison with the background. A Fisher’s exact test
was used, and both an odds ratio and a P-value were assigned to
each comparison.
Data access
WGBS, HumanMethylation450 BeadChip, and RNA-seq data
have been submitted to the European Genome-phenome
Archive (https://www.ebi.ac.uk/ega/) under accession numbers
EGAD00001000672, EGAS00001000841, and EGAS00001001110,
respectively. ChIP-seq and DNase-seq data from the U266 cell
line have been submitted to the European Nucleotide Archive
(https://www.ebi.ac.uk/ena/) under sample accession numbers
SAMEA2165292 and SAMEA2165299, respectively.
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